Synthesis, Characterization, and Application of Core–Shell Co<sub>0.16</sub>Fe<sub>2.84</sub>O<sub>4</sub>@NaYF<sub>4</sub>(Yb, Er) and Fe<sub>3</sub>O<sub>4</sub>@NaYF<sub>4</sub>(Yb, Tm) Nanoparticle as Trimodal (MRI, PET/SPECT, and Optical) Imaging Agents

Xianjin Cui, Domokos Mathe, Noémi Kovács, Ildikó Horváth, Maite Jauregui-Osoro, Rafael Torres Martin de Rosales, Gregory E. D. Mullen, Wilson Wong, Yong Yan, Dirk Krüger, Andrei N. Khlobystov, Maria Gimenez-Lopez, Marianni Semjeni, Krisztián Szigi, Dániel S Veres, Haizhou Lu, Ignacio Hernández, William P. Gillin, Andrea Protti, Katalin Kis Petik, Mark A. Green, and Philip J. Blower

ABSTRACT: Multimodal nanoparticulate materials are described, offering magnetic, radionuclide, and fluorescent imaging capabilities to exploit the complementary advantages of magnetic resonance imaging (MRI), positron emission tomography/single-photon emission commuted tomography (PET/SPECT), and optical imaging. They comprise Fe<sub>3</sub>O<sub>4</sub>@NaYF<sub>4</sub> core/shell nanoparticles (NPs) with different cation dopants in the shell or core, including Co<sub>0.16</sub>Fe<sub>2.84</sub>O<sub>4</sub>@NaYF<sub>4</sub>(Yb, Er) and Fe<sub>3</sub>O<sub>4</sub>@NaYF<sub>4</sub>(Yb, Tm). These NPs are stabilized by bisphosphonate polyethylene glycol conjugates (BP-PEG), and then show a high transverse relaxivity (r<sub>2</sub>) up to 326 mM<sup>−1</sup>s<sup>−1</sup> at 3T, a high affinity to [18F]-fluoride or radiometal-bisphosphonate conjugates (e.g., 64Cu and 99mTc), and fluorescent emissions from 500 to 800 nm under excitation at 980 nm. The biodistribution of intravenously administered particles determined by PET/MR imaging suggests that negatively charged Co<sub>0.16</sub>Fe<sub>2.84</sub>O<sub>4</sub>@NaYF<sub>4</sub>(Yb, Er)-BP-PEG (10K) NPs cleared from the blood pool more slowly than positively charged NPs Fe<sub>3</sub>O<sub>4</sub>@NaYF<sub>4</sub>(Yb, Tm)-BP-PEG (2K). Preliminary results in sentinel lymph node imaging in mice indicate the advantages of multimodal imaging.

INTRODUCTION

The potential clinical and biomedical application of synergistic combinations of magnetic resonance imaging (MRI) with other biomedical imaging modalities, especially positron emission tomography (PET) and optical imaging, has become an emerging topic in the last ten years. Combinations of imaging modalities have the potential to overcome the respective limitations of the individual imaging techniques and provide more accurate and complete physiological and anatomical information for diagnosis and therapy. In certain applications, the combination of imaging techniques into a single contrast agent could also offer the benefits of a reduced dose of contrast agent, a shorter procedure time for both patients and scanners, and the assurance that the different scans reflect contrast located in the same physiological conditions and spatial position. Compared with small molecules or bioconjugates widely used in research and the clinic, nano-
particles (NPs) allow an enhanced imaging signal due to their high payload, as well as a high avidity via multiple targeting ligands attached to their surface. In addition, \(T_2\) or \(T_2^*\) contrast in MRI inherently requires that the contrast agents are particulate. As fluorescent probes, inorganic NPs can not only provide more intense and stable emissions (with peaks tunable from the visible to the near-infrared region), but are generally more thermally stable under laser illumination than organic molecular dyes. The majority of current multimodality contrast agents are based on superparamagnetic iron oxide NPs, while a few examples of Gd\(^{3+}\) or Mn\(^{2+}\) containing NPs have also been reported. Since Weissleder et al.\(^{18}\) reported their pioneering work on multimodal imaging, combinations of NPs and functional polymers\(^{19}\) or polydentate ligands\(^{20,21}\) have been widely applied to obtain multifunctional agents. An alternative approach is hybrid inorganic nanocomposites containing two materials with different properties, such as \(\text{Fe}_3\text{O}_4@\text{NaGdF}_4\) NPs\(^{22}\), \(\text{NaYF}_4@\text{Fe}_3\text{O}_4\)\(^{23}\) and \(\text{Fe}_3\text{O}_4@\text{LnF}_3\)\(^{24}\). For these hybrid inorganic NPs to be used as multimodal imaging contrast, however, a well-defined core−shell structure is crucial to avoid the possibility that some fractions of the NPs behave differently from other fractions, and as a result different imaging modalities reflect the contrast located in different spatial positions.

In this report, we set out to design a trimodal system comprising a magnetic and a fluorescent component with rapid, facile, and efficient radiolabeling under sterile, GMP (Good Manufacturing Practice) conditions with minimal manipulation. Ideally, the system must have a well-defined structure to ensure that the properties do not vary between particles and that the signals of different modalities do not come from different particle types with potentially different in vivo locations. On the basis of this principle, superparamagnetic iron oxide (and its analogues) and \(\text{NaYF}_4\) were selected as the core and shell, respectively, of the proposed combined system. As a well-known host material for up-conversion fluorescence, \(\text{NaYF}_4\) was also reported to be efficient as a substrate for \(^{18}\text{F}\)-fluoride labeling although the detailed mechanism remains unclear.\(^{15,25−31}\) Such a system would allow us to tune the fluorescent properties by doping the \(\text{NaYF}_4\) shell with different lanthanide cations, and optimize magnetic properties by altering the core−shell ratio or the size and composition of the magnetic core. The bishosphonate affinity\(^{25}\) of the \(\text{NaYF}_4\) shell also affords the capability for surface derivatization with radionuclides and with targeting molecules or polymers to control solubility and in vivo behavior.

**RESULTS**

**Structure, Morphology, Composition, and Colloidal Stability of NPs.** \(\text{Fe}_3\text{O}_4@\text{NaYF}_4\) core/shell NPs were synthesized by a two-step thermolysis approach using iron pentacarbonyl and trifluoroacetate salts (Scheme S1 in Supporting Information). Lanthanide cations (Yb, Er, or Tm) were doped into the \(\text{NaYF}_4\) shell for the purpose of up-conversion fluorescence, and Co was doped into the \(\text{Fe}_3\text{O}_4\) core to adjust the magnetic property of NPs. Transmission electron microscope (TEM) images (Figure 1) revealed that the NPs with different doping shared a similar size and morphology. X-ray powder diffraction (XRD) patterns implied that these \(\text{Fe}_3\text{O}_4@\text{NaYF}_4\) core/shell NPs consisted of two distinct phases, \(\text{Fe}_3\text{O}_4\) and \(\alpha\)-\(\text{NaYF}_4\) (Figure S1). High resolution transmission electron micrograph (HRTEM) studies of NPs \(\text{Fe}_3\text{O}_4@\text{NaYF}_4\) (Yb, Tm) showed atomic lattice fringes of 2.97 Å associated with the (022) and (202) planes of cubic \(\text{Fe}_3\text{O}_4\) and 1.72 and 2.94 Å corresponding to the (022) and (200) planes of cubic \(\text{NaYF}_4\) respectively (Figure 2a). The angle between the (022) and (202) planes was calculated as 60°, consistent with the value measured on the HRTEM image. The electron diffraction patterns were obtained by the fast Fourier transform analysis of the HRTEM image. Two sets of diffraction patterns for \(\text{Fe}_3\text{O}_4\) and \(\text{NaYF}_4\) were obtained, and each spot was **Figure 1.** TEM images at low and high magnifications, and the size distribution of \(\text{Co}_{0.16}\text{Fe}_{2.84}\text{O}_4@\text{NaYF}_4\) (Yb, Er) NPs (a−c) and \(\text{Fe}_3\text{O}_4@\text{NaYF}_4\) (Yb, Tm) NPs (d−f). The particle size was determined on TEM and N is the number of particles counted for size analysis.

**Figure 2.** HRTEM studies of NPs: (a) HRTEM images of \(\text{Fe}_3\text{O}_4@\text{NaYF}_4\) (Yb, Tm); (b) fast Fourier transform of the selected area in part a, showing two sets of diffraction patterns. The diffraction pattern marked in blue belonged to cubic \(\text{Fe}_3\text{O}_4\), and the one marked in red was assigned as cubic \(\text{NaYF}_4\); (c) high angle annular dark field image of \(\text{Fe}_3\text{O}_4@\text{NaYF}_4\) (Yb, Tm), showing the Z contrast difference between the shell and core of particles induced by a slightly higher average atomic number in the shell after doping with heavy atoms Yb and Tm; (d) HRTEM image revealed the core−shell structure of NP \(\text{Co}_{0.16}\text{Fe}_{2.84}\text{O}_4@\text{NaYF}_4\) (Yb, Er). Atomic lattice fringes 2.97 and 4.14 Å corresponded to (022) and (200) planes of \(\text{Fe}_3\text{O}_4\) respectively. The inset is a fast Fourier transform of the micrograph.
TEM. glycophyl conjugates (BP-PEG), as shown in Scheme S1 and form by ligand exchange with bisphosphonate polyethylene covered with oleylamine, were converted to a water-soluble codoped NaYF4 shells appeared brighter than the Fe3O4 cores. The core-shell structure of FeO3O4@NaYF4 NPs was also investigated by bright field HRTEM. For instance, the HRTEM image of Co0.16Fe2.84O4@NaYF4(Yb, Er) NPs in Figure 2d showed a distinct contrast difference between the Co-doped FeO3O4 core and the Yb/Er codoped NaYF4 shell, while the electron diffraction pattern indicated the crystalline nature of the core. Despite the presence of heavy atoms Yb and Er, the shell appeared brighter on bright field TEM image, since the contrast is determined by the thickness and crystallinity of the specimen, as well as its elemental composition. The atomic lattice fringes of 2.97 and 4.14 Å were associated with (022) and (200) planes, respectively, of the cubic FeO3O4 phase. The doping of Co into the FeO3O4 lattice, was confirmed by energy dispersive X-ray spectroscopy (EDX) (Figure S2). Composition studies on Co/Yb/Er doped NPs were also carried out by X-ray photoelectron spectroscopy (XPS) and inductively coupled plasma mass spectrometry (ICP-MS) (Figure S3, Tables S3 and S4). ICP-MS results indicated a formulation of Co0.16Fe2.84O4 for the core, and the unexpected low Co to Fe ratio was probably due to an incomplete decomposition of Co(acac)2. The molar ratio of Y:Yb:Er was measured by ICP-MS as 79.3:18.6:2.1, consistent with the ratio of starting materials (Y2O3, Yb2O3, and Er2O3). By comparing the relative content of Fe, Co, Y, Yb, and Er obtained by ICP-MS and XPS (Table S3), it was clear that dramatically less Fe and Co was detected by the surface technique XPS, than by ICP-MS or EDX. This is consistent with the proposed core-shell structure observed by TEM.

The Co0.16Fe2.84O4@NaYF4(Yb, Er) and FeO3O4@NaYF4(Yb, Tm) core-shell NPs described above, which are inevitably covered with oleylamine, were converted to a water-soluble form by ligand exchange with bisphosphonate polyethylene glycol conjugates (BP-PEG), as shown in Scheme S1 and Figure S4. The appearance of characteristic peaks associated with the PEG chain at 1109, 958, and 837 cm−1 on the IR spectrum of PEGylated NPs (Figure S5), diffraction peaks at 19° and 23° in the XRD pattern (Figure S1)33,34 and a mass loss of up to 52.7% starting from over 200 °C on thermogravimetric curves (Figure S6) confirmed the attachment of BP-PEG.

Dynamic light scattering (DLS) experiments demonstrated that the NPs were highly dispersed in water after surface modification with BP-PEG, showing a hydrodynamic diameter (Dh) of 44 nm for Co0.16Fe2.84O4@NaYF4(Yb, Er) NPs over a concentration range from 0.01 to 1 mg/mL. Suspensions of PEGylated NPs were extremely stable and could not be precipitated by centrifugation at 10 000 rpm for 30 min. No aggregation was observed during a period of 14 h by DLS. This extreme long-term stability is presumed to be due to the strong coordinative interactions between the bisphosphonate groups and metallic sites on the surface of NPs, in keeping with earlier observations.8,21

Radiolabeling of NPs. The NaYF4 shell of NPs was chosen in part due to a high affinity for [18F]-fluoride, as fluoride binding to NaYF4 has been reported previously.27,28 Indeed, the 18F-labeling efficiency of Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG NPs (0.1 mg) was up to 38.5% after a brief (5 min) incubation with aqueous no-carrier-added [18F]-fluoride at room temperature (Table S5). These observations were consistent with the core/shell structure of the NPs since neither Co0.16Fe2.84O4 nor FeO3O4 alone showed significant binding to [18F]-fluoride.35 The labeling efficiency (% of radionuclide bound) was found to increase with the amount of NPs, which is consistent with previous observations.35 The serum stability of Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG NPs prelabeled with [18F]-fluoride was determined by incubating the fluorinated particles in human serum for intervals of up to 2 h and measuring the fraction of activity remaining bound to NPs with a gamma counter after separating NPs from the supernatant by centrifugation in a NanoSep device with a cutoff size of 10K (Figure S7). Over 85% of the 18F remained bound to the NPs after incubation in serum up to 2 h, slightly less than ca. 90% reported in PBS (phosphate buffered saline).28 The initial partial release of 18F from NPs into serum seemed to be a rapid process since no further changes was observed after 15 min.

Because of the previously observed strong interactions between phosphate groups and NaYF4 NPs and iron oxide NPs,21,33 it was expected that the NPs would have a high affinity for radiometal chelate-bisphosphonate conjugates.20,21,33 Both Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG and FeO3O4@NaYF4(Yb, Tm)-BP-PEG particles showed a high affinity to 99mTc-DPA-ale (data not shown) and 64Cu(DTCBP)2, which has two uncoordinated bisphosphonate groups,8,21 with up to 96% labeling efficiency (Table S5). The ability to bind readily with [18F]-fluoride and bisphosphonate conjugates of 64Cu and 99mTc offers potential applications in PET and SPECT imaging.

Magnetic Resonance Properties. The r1 and r2 relaxivities were measured in aqueous solution at magnetic fields of 3 T and 7 T, to determine the feasibility of using these core/shell structures as MRI contrast agents. The values of relaxivities r1 and r2 of Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG in aqueous solution at 3 T were calculated as 5 and 102 mM−1 s−1, respectively (Figure 3a). At a higher magnetic field (7 T), r1 and r2 were found to be 2 and 159 mM−1 s−1, respectively. FeO3O4@NaYF4(Yb, Tm)-BP-PEG NPs showed a r1 relaxation of up to 326 mM−1 s−1, and a r1 value of 3 mM−1 s−1 at 3 T (Figure S8). A high r2 value and r2/r1 ratio for both Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG and FeO3O4@NaYF4(Yb, Tm)-BP-PEG demonstrated their excellent potential as T2 or T2* contrast agents in MRI. Indeed, FeO3O4@NaYF4(Yb, Tm)-BP-PEG NPs, as a multimodal contrast, provided a higher r1 relaxation (326 mM−1 s−1) than clinically used Feridex (r1 ≈ 107 mM−1 s−1, r2/r1 ≈ 4.65)57 and most iron oxide or iron nanoparticle-based single-modality T2 MRI contrast agents reported so far.17,18

Optical Properties. NaYF4 and its paramagnetic analogue NaGdF4 have been intensively investigated as host materials, into which rare earth cations can be doped or codoped to achieve down-conversion or up-conversion fluorescence.16,25,40,41 In order to incorporate this type of optical activity into our multimodality contrast NPs, lanthanide cations
Er or Tm (active cations) were codoped with Yb³⁺ (sensitizer) into the NaYF₄ layer. Up-conversion fluorescent emission was then observed under excitation with a 980 nm laser. Two emission features for Fe₃O₄@NaYF₄(Yb, Er)-BP-PEG at 700 and 800 nm were observed and assigned to the transitions 3F₄ to 3H₆ and F₄ to 3H₄ of Tm³⁺ (Figure S9), while three emission features of Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG at 525, 550, and 650 nm, were assigned to the transitions from 2H₁₁/₂ to 4I₇/₂, 4F₃/₂ to 4I₇/₂, and 4F₉/₂ to 4I₇/₂ of Er³⁺ (Figure 3b). To explore the application in fluorescent imaging, Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG NPs were incubated in vitro with a cultured monolayer of HeLa cells and physiological saline for 24 h. Green fluorescent signals from NPs associated with cytoplasm of living HeLa cells were observed (Figure 3c), and the defined structure and position of the green fluorescent emission features of Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG at 325, 550, and 650 nm, were assigned to the transitions from 2H₁₁/₂ to 4I₇/₂, 4F₃/₂ to 4I₇/₂, and 4F₉/₂ to 4I₇/₂ of Er³⁺ (Figure 3b).

**In Vivo Studies.** To investigate the biodistribution in vivo of these NPs after systemic (intravenous) administration, solutions of the ¹⁸F-radiolabeled Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG (10K) (130 μL, 5.6 Mbq, 40 μg Fe) and Fe₃O₄@NaYF₄(Yb, Tm)-BP-PEG (2K) NPs (150 μL, 3.7 Mbq, 45 μg Fe, Tables S1 and S2) were injected into the tail veins of two different mice, immediately followed by imaging by coregistered PET-MRI on a preclinical nanoScan PET•MRI scanner with a 1 T magnetic field (Mediso Ltd., H-1047, Budapest, Hungary). In both cases, radioactivity was taken up by the spleen and liver within 45 min, and accumulated to a small extent in the bladder after 60 min (Figures 4a−d and S10 and S11). This biodistribution pattern for radioactivity was matched by darkening contrast observed on MR images (Figure 4e,f). Very little radionuclide accumulation in the skeleton (characteristic of free [¹⁸F]-fluoride) was observed, indicating that the NP-radiolabel bond was reasonably stable in vivo over a 1 h time period. The later increase in radioactivity in the bladder and bone, which coincided with a decrease of radioactivity in the liver, suggests that the particles may be degraded in the liver with release of free fluoride.

In vivo PET/MRI imaging of the lymph node (LN) system was carried out using a preclinical nanoScan integrated PET/MRI system (Mediso, Budapest, Hungary) with a 1 T magnet, utilizing ¹⁸F-labeled Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG (10 K) or Fe₃O₄@NaYF₄(Yb, Tm)-BP-PEG (2 K) NPs as probe. After injection of 20 μL of a solution of these NPs containing 6.3 Mbq radioactivity and 20 μg Fe into the rear right foot pad of a mouse (C57BL/6, female, 6−7 weeks old, 20 g), coregistered PET and MRI images were recorded 6 h post injection. The LNs were clearly visible on PET images (Figure S5). The most prominent signal was from the popliteal LN, which is the nearest draining LN from the injection point, and the next most prominent signal was from the medial iliac LN (Figure 3b). Both LNs were evident on the MR image with a decrease in MR T₂ signal intensity compared to the

---

**Figure 3.** (a) Curve of relaxivity against the concentration of Fe+Co for Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG at 3T and 7T (concentration of Fe and Co determined by ICP-MS); (b) up-conversion spectrum of Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG under excitation by a 980 nm laser; (c) transmitted infrared image of HeLa cell culture in monolayer (gray scale) incubated with Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG and fluorescence emission image (green, 490−560 nm) overlaid. Excitation wavelength 980 nm. Arrows show green fluorescence from cell-incorporated particles.

**Figure 4.** PET/MRI images showing the dynamic biodistribution of ¹⁸F radiolabeled NPs. MR images were taken immediately after PET scans, 2 h post the injection of NPs, and they were fused with PET images taken at three different time intervals (0−15 min, 45−60 min, and 105−120 min). (a) PET/MR fused image at 0−15 min, showing radioactivity mainly confined to blood pool with minor uptake in liver; (b) PET/MRI fused image at 45−60 min showing increased accumulation in liver and minor uptake in skeleton; and (c) PET/ MR fused image at 105−120 min showing increased uptake in skeleton and bladder; (d) whole body PET image showing uptake of radiolabeled negatively charged NPs Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG (10K) (maximum intensity projection, 30−45 min), showing radioactivity mainly confined to blood pool, with little activity in bone or bladder; (e) MR image of the mouse prior to the injection of Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG (10K) NPs; (f) MR image of the mouse 2 h post injection of Co₀.₁₆Fe₂.₈₄O₄@NaYF₄(Yb, Er)-BP-PEG (10K) NPs. The series of images (a) to (d) shows predominantly blood pool retention of the labeled NPs at early stages post injection, giving way to liver uptake and then bone and bladder, consistent with release of radioactivity from nanoparticles in liver as free fluoride.
contralateral (control) LNs (Figure S12). Interestingly, a PET signal was also detected at the more distant lumbar aortic LN (Figure 5d and e). However, no contrast was observed at this area on MR image post injection, due to the relatively poor sensitivity of MRI (Figures 5c and S12). Because of the long delay post injection (6 h) skeletal uptake of radioactivity was also observed in the PET image consistent with gradual release of fluoride from the NPs in vivo.

To further explore the potential value of this class of NPs, a more detailed lymph node study by PET/MRI imaging was undertaken, investigating the popliteal LN in response to an acute inflammatory stimulus in the foot. A solution of $^{18}$F-labeled Fe$_{3}$O$_{4}$@NaYF$_{4}$(Yb, Er)-BP-PEG (20 μL, 4.5 MBq, 20 μg Fe) was injected into each of the two rear footpads of a female C57BL/6 mouse in which only the right leg was inflamed. Again, uptake of particles in both popliteal and iliac LNs was identified by PET and MRI (Figures 6, S13) 6 h post injection. Interestingly, the right popliteal LN appeared on the MR image as a white spot with a darkened background while the left counterpart displayed a black spot with a white background typical of a healthy lymph node (Figure 6h and i). A possible biological rationale for this behavior is that the LPS induced a macrophage response that may have taken up sufficient numbers of the nanoparticles to be detectable by MRI. As macrophages migrating to draining lymph nodes do not enter the lymph node, but rather stay in the capsular layer, this would lead to the observed signal distribution. Thus, while PET has the sensitivity to easily locate the relevant lymph node, MRI provided the resolution lacking in PET to delineate disease-related and hence potentially diagnostic changes in the fine structure and distribution of contrast agents in and around the LN. A control experiment was carried out with $^{18}$F-fluoride only (e–g), a whole body PET image showing uptake of radiolabeled NPs (maximum intensity projection; bone uptake was observed due to gradual release of fluoride from NPs due to the 7 h delay post injection of NPs); (b) PET image showing popliteal and iliac lymph nodes (coronal section); (c) PET/MRI fused image (coronal section); (d) MR image (coronal section) with darkening contrast inside popliteal lymph node at left-rear (white circle) and “outside” lymph node at the inflamed right-rear (red circle) induced by injection of 30 μL 0.67 mg/mL lipopolysaccharide (LPS) 18 h prior to imaging, and at iliac lymph node; (e) PET image following injection of $^{18}$F-fluoride showing no contrast in lymph nodes in the absence of NPs and prominent uptake by skeleton; (f) PET/MRI fused image following injection of $^{18}$F-fluoride, showing no radioactivity associated with lymph nodes; (g) MR image showing no difference between normal popliteal lymph node at left-rear leg (white circle) and the inflamed lymph node at right-rear leg induced by injection of 30 μL 0.67 mg/mL LPS 18 h prior to imaging; (h–k) enlarged MR images of corresponding lymph nodes.

![Figure 5. PET/MRI images of a normal young C57BL/6 mouse showing LNs with dual contrast provided by $^{18}$F-labeled C$_{60,18}$Fe$_{2,84}$O$_{2}$@NaYF$_{4}$ (Yb, Er)-BP-PEG: (a) schematic diagram showing the connections between lymph nodes and the injection point (mouse in supine position); (b) whole body PET image showing uptake of radiolabeled NPs 7 h post injection (maximum intensity projection, mice in prone position); (c) MR image with darkening contrast at popliteal LN (coronal section); (d) PET image showing radioactivity at popliteal, inguinal, lumbar aortic, and aorta LN area (coronal section); and (e) PET/MRI fused image showing popliteal, inguinal, lumbar aortic, and aorta LN (coronal section). Some bone uptake of radioactivity is observed in (b), (d), and (e) due to gradual release of fluoride from the particles due to the long delay (7 h post injection of $^{18}$F radiolabeled NPs) between injection and imaging.

![Figure 6. Lymph node PET/MRI imaging of a mouse with inflamed right leg using $^{18}$F-labeled Fe$_{3}$O$_{4}$@NaYF$_{4}$ (Yb, Tm)-BP-PEG NPs (a–d) or with $^{18}$F-fluoride only (e–g): (a) whole body PET image showing uptake of radiolabeled NPs (maximum intensity projection; bone uptake was observed due to gradual release of fluoride from NPs due to the 7 h delay post injection of NPs); (b) PET image showing popliteal and iliac lymph nodes (coronal section); (c) PET/MRI fused image (coronal section); (d) MR image (coronal section) with darkening contrast inside popliteal lymph node at left-rear (white circle) and “outside” lymph node at the inflamed right-rear (red circle) induced by injection of 30 μL 0.67 mg/mL lipopolysaccharide (LPS) 18 h prior to imaging, and at iliac lymph node; (e) PET image following injection of $^{18}$F-fluoride showing no contrast in lymph nodes in the absence of NPs and prominent uptake by skeleton; (f) PET/MRI fused image following injection of $^{18}$F-fluoride, showing no radioactivity associated with lymph nodes; (g) MR image showing no difference between normal popliteal lymph node at left-rear leg (white circle) and the inflamed lymph node at right-rear leg induced by injection of 30 μL 0.67 mg/mL LPS 18 h prior to imaging; (h–k) enlarged MR images of corresponding lymph nodes.](image)

**DISCUSSION**

We have presented a novel type of inorganic core—shell NP with built-in magnetic, fluorescent, and radiolabeling properties, which show potential as probes for MRI, optical imaging, and PET/SPECT imaging. Stealth features to evade the immune system and prevent opsonization are required in some imaging and therapy applications to reduce the off-target localization and toxicity of NPs, prolong their circulation time in the blood pool (where this is desirable) and deliver them to specific sites. PE Gylation, using the novel bisphosphonate derivative to anchor the PEG to the NP surface, was employed not only to stabilize the particles against aggregation in solution by the steric effect, but also to modify their circulation time. PEGylated ligands with different polymeric chain lengths...
were introduced on the surface of Co_{0.16}Fe_{2.84}O_4@NaYF_4(Yb, Er) and Fe_{2}O_3@NaYF_4(Yb, Tm) NPs, to produce water-soluble versions: Co_{0.16}Fe_{2.84}O_4@NaYF_4(Yb, Er)-BP-PEG and Fe_{2}O_3@NaYF_4(Yb, Tm)-BP-PEG. In both cases, PEGylation, small hydrodynamic size (<100 nm) and low zeta-potential offer the opportunity to control circulation time and avoid immediate reticuloendothelial clearance where this is desired for specific applications. Indeed, the longer-chain PEGylation of Co_{0.16}Fe_{2.84}O_4@NaYF_4(Yb, Er) (10 K) (M_w = 10 kDa, n ~ 227) resulted in a slightly negative zeta potential (~10 mV) and delayed clearance compared to Fe_{2}O_3@NaYF_4(Yb, Tm)-BP-PEG (2 K) (M_w = 2 kDa, n ~ 45, and zeta potential of +10 mV) (Figures 4, S10 and S11), although surface density of PEG(10K) is less than that of PEG(5K) (37.6% vs 52.7%). This suggests that the length of the PEG chain and zeta potential of NPs play important roles in biodistribution. The circulation time of Co_{0.16}Fe_{2.84}O_4@NaYF_4(Yb, Er) (10 K) is shorter than that reported previously for PEGylated iron oxide. This may be attributable to reduced PEG surface coverage (36.7% vs 61%, Figure S6). The extent of PEGylation and the chain length may therefore be optimized for specific applications. Particle size combined with surface properties also plays an important role in enhancing lymphatic transport. The smaller particles (less than 100 nm) are transported and taken up more readily, whereas the larger NPs are likely to remain in the injection site. PEGylation can improve the uptake in lymph nodes by reducing the nonspecific interaction between particles and proteins of the interstitium.

Convenient incorporation of readily available imaging radioisotopes such as [^{18}F]-fluoride is important for applications in radionuclide imaging. Because of the short half-life and the need for GMP conditions in the daily production of radiopharmaceuticals at hospital sites, radiolabeling procedures must be as simple as possible and avoid the requirement of costly specialist facilities. Inorganic nanoparticulate materials have previously been reported that bind [^{18}F]-fluoride rapidly with high efficiency under mild conditions. The NaYF_4 shell of the core–shell system can efficiently carry [^{18}F] as well as other radionuclides such as [^{99m}Tc] or [^{64}Cu] conjugates, and the radiolabeling of these particles is extremely simple, quick, and efficient. Release of fluoride from the NPs, allowing uptake in bone, is relatively slow compared to both lymphatic transport and reticuloendothelial clearance, allowing imaging of both processes (Figures 4–6, S10 and S13).

The fluorescent properties of the codoped NaYF_4 shell allowed microscopic fluorescence imaging at the cellular level (Figure 3d), and could be explored as a potential visual guide during surgery. NPs with stronger fluorescent emissions can be developed by deposition of additional pure or doped NaYF_4 layer on the core–shell structures to suppress the energy transfer to surface quenchers (impurities, ligands, and solvent molecules) and to modify local crystal structure surrounding the doping cations. The balance between the thickness of the fluorescent and radiolabeled shell of NaYF_4 and the size and composition of the magnetic core could be adjusted to optimize the optical and magnetic properties, respectively, for applications as multimodal imaging agents. For example, NPs Fe_{2}O_3@NaYF_4(Yb, Tm)-BP-PEG showed a much higher r_2 than NPs Co_{0.16}Fe_{2.84}O_4@NaYF_4(Yb, Er)-BP-PEG (326 mM^{-1}S^{-1} vs 102 mM^{-1}S^{-1}), though both of them share a similar particle size and core-to-shell ratio (Figure S9).

Accurate location and identification of lymph nodes and detection of the pathology within them is important for studies of tumor metastasis in humans, including the identification of sentinel lymph nodes during surgery, and in rodent models for the study of immune responses to foreign antigens, transplants, and tumors. The in vivo imaging studies reported here, although not matched to a current typical clinical imaging protocol, are relevant to sentinel node imaging in support of cancer surgery and suggest several ways in which combined coregistered MR and PET imaging with a single contrast agent can provide additional information and increased confidence in image interpretation. The PET images, by virtue of lower content of irrelevant detail, allow easy identification of regions for closer examination by MRI. In addition, the greater sensitivity of PET allows detection of relevant lymph nodes distant from the disease site (e.g., Figure 5c–e) which is unlikely to be detected by MRI alone (Figure 6). The accurate presurgical location of iliac and popliteal LNs in context of the anatomy of the mouse was achieved only when the PET and MRI images were coregistered and overlaid. The improved soft tissue contrast offered by MRI compared to CT, which is conventionally combined with PET and SPECT, should offer improved presurgical mapping of lymph node locations. Moreover, the additional anatomical and functional detail in soft tissues permitted by contrast MRI (e.g., the differences in structure and contrast agent distribution in and around the lymph node between left and right popliteal nodes) in regions initially identified by PET, but which the limited resolution of PET cannot show, have the potential to provide useful diagnostic information beyond simply identifying presurgically the location of the sentinel node. This is likely to provide synergistic value when used during imaging with the new generation of clinical combined PET/MR scanners now appearing in hospitals. The fluorescence should enable further visual observation of these anatomical and functional changes during surgery and subsequently during pathological examination of excised tissues. Data from each of these imaging modalities can be combined, with reassurance that the signal comes from the same contrast agent, and hence the same biodistribution, in each modality.

**CONCLUSIONS**

In summary, we have reported the synthesis and characterization of the first series of Co_{0.16}Fe_{2.84}O_4@NaYF_4 core–shell based NPs in which the shell was codoped with lanthanide cations providing optical imaging capabilities, and could also be radiolabeled with [^{18}F]-fluoride and radiometal–bisphosphonate conjugates, while the iron oxide-based core provided MR contrast. We have shown for the first time that the NaYF_4 shell can be stably modified with bisphosphonate-derived PEG and radionuclide conjugates. The particles offer trimodal imaging using PET/SPECT, MRI, and up-conversion fluorescent imaging. The NPs showed excellent colloidal stability in water and a narrow size distribution after surface modification with BP-PEG. The simple and quick radiolabeling process is a major advantage for use of these materials as PET/SPECT tracers and is essential for routine clinical use. Our in vivo studies in lymph nodes demonstrated the potential advantages of combining imaging modalities using NPs as multimodal (PET, MRI, and optical) imaging agents. In addition, these NPs could also potentially act as visual guides during surgery due to their up-conversion fluorescent properties.
**EXPERIMENTAL SECTION**

**Materials and General Characterization.** Chemicals were obtained from commercial sources and used as purchased without further purification unless otherwise specified. Human serum was obtained by filtering human male AB plasma from Sigma-Aldrich with Millex IC 0.22 μm (13 mm) hydrophilic PTFE filters. Water was obtained from an ELGA PureLab OptionQ system. Organic solvents oleylamine (90%, technical grade) and 1-octadecene (90%, technical grade) came from Fisher Scientific Ltd. Rare earth trilfluoroacetate salts were prepared in house from corresponding rare earth oxides purchased from Sigma-Aldrich. Typically, the mixed powder of Y2O3, Yb2O3, and Er2O3 (molar ratio Y:Yb:Er = 78:20:2) was dissolved in trifluoroacetic acid at 60 °C, and water was removed by rotary evaporator to obtain light pink or white M(CF3COO)2 powder. 18F and 64Cu were produced using the PET Imaging Centre cyclotron at St Thomas' Hospital, London, UK. 99mTc-MDP was obtained from the Nuclear Trust. Thermogravimetric analysis (TGA) was performed under a flow of nitrogen (20 mL/min) with a heating rate of 5 °C/min using a TA SDT-600 thermogravimetric analyzer. XRD were recorded at room temperature on a PANalytical X’Pert PRO diffractometer using Cu Kα radiation (λ = 1.540598 Å) at 40 kV, 40 mA, at a scan speed of 0.02°/s and a step size of 0.026° in 2θ. XPS spectra were recorded using a Kratos AXIS ULTRA with monochromated Al K radiation (10 kV anode potential, 15 A emission current) in transmission mode (80 eV pass energy). TEM images were taken on Tecnai FEI T20 at Centre for Ultrastructural Imaging, King’s College London, and HRTEM on JEOL 2100 at Nottingham Nanotechnology and Nanoscience Centre, Nottingham University, and on T20 at LEMAS, Leeds University. IR spectra were recorded on a PerkinElmer spectrum 100. DLS measurements were performed with a Malvern Instruments with a measured angle 175° and a 632.8 nm laser. Zeta potential for all samples was measured in neutral aqueous solution with a pH value ≈ 7. Up-conversion spectra were obtained at Queen Mary University of London, using a 980 nm continuous wave diode laser modulated at a frequency of 13 Hz. The photoluminescence was dispersed in a Triax S50 spectrometer and detected with a Hamamatsu R5509-72 photomultiplier.

**Synthesis of Co0.16Fe2.84O4@NaYF4(Yb, Er) NPs.** First, Co(acac)2 (514 mg, 2 mmol) was dissolved in a solvent mixture of 5 mL oleylamine and 15 mL 1-octadecene at 120 °C under vacuum. Under N2 atmosphere, Fe(CO)5 (4.5 mmol, 0.6 mL) was injected into the solution of Co(acac)2, and then the resultant solution was heated up to 250 °C within 15 min under stirring. After being kept at 250 °C for 1 h, a solution obtained by dissolving CF3COONa (800 mg, 5.9 mmol) and M(CF3COO)3 (M = Y, Yb, or Er; Yb:Er = 78:20:2; 1000 mg; 2 mmol) in 10 mL oleyl amine and 10 mL 1-octadecene at 120 °C under vacuum, was added into the resultant black slurry under N2 by syringe. The mixture was kept to 340 °C with a heating rate 10 °C/min. After being kept at 340 °C for 15 min, the mixture was cooled down to room temperature by removing the heating bath. The product was precipitated out by adding 30 mL ethanol and then collected by a magnet. The particles were redispersed in hexane and precipitated with ethanol twice more. Fe3O4@NaYF4(Yb, Tm) NPs was obtained using a similar approach as Co0.16Fe2.84O4@NaYF4(Yb, Er) NPs.

**Synthesis of Fe3O4@NaYF4(Yb, Tm) NPs.** First, CF3COONa (800 mg, 5.9 mmol) and M(CF3COO)3 (M = Y, Yb, or Tm; Yb:Tm = 75:20:5; 1000 mg; 2 mmol) were dissolved in 10 mL oleyl amine and 10 mL 1-octadecene at 120 °C under vacuum for at least 30 min. Under N2 atmosphere, Fe(CO)5 (7 mmol, 0.9 mL) was injected into the solution, and then the resultant solution was heated up to 200 °C within 15 min under stirring. The mixture was maintained at 200 °C for 20 min under N2, and then heated to 340 °C with a heating rate 10 °C/min. After being kept at 340 °C for 1 h, the mixture was cooled down to room temperature by removing the heating bath. The product was precipitated out by adding 30 mL ethanol and then collected by a magnet. The particles were redispersed in hexane and precipitated with ethanol twice more.

**PEGylation of NPs.** BP-PEG was prepared as described elsewhere 1. The mixture was treated with excess hexane to precipitate out NPs. To remove uncoupled ligands, the product was redispersed in ethanol and precipitated out by adding hexane. The same procedure was carried out to conjugate BP-PEG (2 kDa) with Fe3O4@NaYF4(Yb, Tm) NPs.

**Radio labeling of NPs with [18F]-Fluoride, 99mTc-DPA-ale, or 64Cu-(DTCBP).** Typically, 100 μL of [18F]-fluoride in 18O-water direct from target was added into a Nanosep centrifugal device with omega membrane (from Sigma-Aldrich, molecular weight cutoff size = 30 000) containing 400 μL NP suspension. After incubation at room temperature for 5−15 min, the suspension was centrifuged at 10 000 rpm (Eppendorf centrifuge 5424) for 10 min to separate the NPs from solution. The radioactivity remaining in filtrate and on NPs was measured by a gamma counter or a CRC-25K dose calibrator (Capintec, USA). Labeling efficiency was calculated by dividing the radioactivity on NPs by the sum of that in supernatant and on NPs. Triplicate measurements were carried out at each concentration of NPs. Radiolabeling with 99mTc-DPA-ale or 64Cu bis(dithiocarbamate) biphosphonate conjugate ([64Cu-(DTCBP)]2) was carried out via the previously published procedures.8,21

**Stability of [18F]-Fluoride Labeled NPs in Human Serum.** [18F]-Fluoride labeled radiolabeled NPs were dissolved in 500 μL serum and left at 37 °C for different periods of time. Then NPs were separated by Nanosep centrifugation at 14 000 rpm (Eppendorf centrifuge 5424) for at least 15 min. The radioactivity in serum and on NPs was measured by gamma counter, respectively. Triplicate samples were measured at each time point.

**T1, T2, and T2* Relaxivity Measurements.** MR imaging was performed with a standard extremity flex coil on a clinical 3T Philips Achieva MRI scanner (Philips Healthcare, Best, The Netherlands). T1 mapping was obtained by using a 2D sequence that employs two nonselective inversion pulses with inversion times ranging from 20 to 2000 ms, followed by eight segmented readouts for eight individual images.49 The two imaging trains result in a set of 16 images per slice with increasing inversion times (FOV = 200 × 200 mm2, matrix = 200 × 179 mm2, in-plane resolution = 1 × 1.12 mm2, measured slice thickness = 3 mm, slices = 16, TR/TE = 3.2/1.6 ms, FA = 10°). T2 was determined with a 2D multispin−echo sequence (FOV = 200 × 200 mm, matrix = 200 × 200, measured slice
thickness = 3 mm, ETL = 5, TE = 10 ms, TR = 725 ms, FA = 90°). The acquired imaging data were transferred to a computer running Matlab and analyzed using an in-house Matlab tool to receive the relaxation times $T_1$ and $T_2$ for each SPIO concentration. Excel was used to plot the relaxation rates over the concentration and to fit a linear function to determine the relaxivity values (i.e., gradient of linear fit).

**In Vivo PET/MRI Imaging.** Five 6–7-week-old female C57 black mice with a weight of 20–21 g were used. Animal experiments were carried out at Nanobiotechnology & In Vivo Imaging Center of Semmelweis University, with permission from the local institutional animal ethics committee and in compliance with the relevant European Union and Hungarian regulations. Inflammation was induced by injection of 30 μL 0.67 mg/mL lipopolysaccharide (LPS) into the footpad of the right-rear leg, 18 h prior to the injection of NPs. PET/MRI images were recorded on a nanoScan integrated PET/MRI system (Mediso, Budapest, Hungary) in which the MR is a preclinical 1T MRI scanner (M2, Aspect Imaging) with horizontal bore magnet, solenoid coil (diameter of 35 mm), and 450 mT/m gradients. Mice were anaesthetized with isofluorane and placed in prone position on the MRI bed. In the case of lymph node imaging with NP $\text{Ce}_{0.18}\text{Fe}_{2.82}@\text{O}_1\text{O}_4@\text{NaYF}_4(Yb, Er)$-BP-PEG, after the precontrast MR scan, 20 μL NPs solution in saline containing 6.3 MBq $^{18}F$-fluoride radioactivity and 40 μg Fe was injected into the footpad of the right-rear leg (Tables S1 and S2). PET scanning was started 6 h after injection. Acquisition took place in 1–5 coincidence mode with 5 ns coincidence window, 400–600 keV energy window, 94.7 mm scan range, and acquisition time was 30 min. A 3D expectation maximization (3D EM) PET reconstruction algorithm (Mediso Tera-Tomo TM) was applied to produce PET images including corrections for attenuation and scatter, dead time, decay, and randoms. After 8 iterations the reconstruction stopped, resulting in images with 0.1 mm voxel size and time frames of 8 × 15 min. MR scanning was performed immediately after PET. The images of the two modalities were fused automatically. The same procedure was carried out for intravenously injected contrast agent, but radiolabeled nanoparticles were injected via the tail vein and PET scanning started immediately after the injection with total acquisition time of 2 h instead of 30 min.

**In Vitro Fluorescent Cell Imaging.** A monolayer HeLa cell culture (grown in RPMI 1640 medium supplemented with 2% of fetal calf serum) was incubated for 24 h with the nanoparticle dispersion. Particles that were not attached or internalized to cells were washed by physiological saline. Cell culture was imaged in the Femto2D two-photon microscope, under an excitation laser of 980 nm. We also imaged a washed culture was imaged in the Femto2D two-photon microscope, transmitted infrared light and green fluorescence were recorded in both cases in order to find the inner part of the cells. A few distancing particles in the solution above the cells were clearly distinguishable from those that did not move, attached inside the cells. Transmitted infrared light and green fluorescence emission (490–560 nm) was detected in separate channels.

**ASSOCIATED CONTENT**

**Supporting Information**

The detailed information for in vivo imaging; synthesis scheme of NPs; XRD, EDX, XPS, ICP-MS, and IR results of NPs; structure of ligands and functionalized NPs; TGA; radio-labeling; MR relaxivities of NPs; stability of radiolabeled NPs; dynamic biodistribution of NPs; PET/MR images; and pre- and postcontrast MR images. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.bioconjchem.5b00338.

**AUTHOR INFORMATION**

**Corresponding Authors**

*E-mail: mark.a.green@kcl.ac.uk.*

*E-mail: philip.blower@kcl.ac.uk.*

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

We thank Prof. Martin Schrøder at School of Chemistry, Nottingham University, for the access to TGA equipment, Dr. Michael Ward at LEMAS Centre, Leeds University, for his assistance on HRTEM, Drs. Alice Warley and Gama Vizcay, at Centre for Ultra Structural Imaging, King’s College London for TEM, Dr. Hatao Ye at School of Engineering and Applied Science, Aston University for XPS, Prof. Shuhong Yu and Mr. Liang Dong at School of Chemistry, University of Science and Technology of China, for up-conversion spectrum measurement. The help from László Papp, Sándor Hóbor and Gábor Németh from Mediso is kindly acknowledged. RTMR and DM would like to thank EU COST action TD1007 on PET-MRI. This research was supported by the Centre of Excellence in Medical Engineering Centre funded by the Wellcome Trust and EPSRC under grant number WT088641/Z/09/Z, and the King’s College London and UCL Comprehensive Cancer Imaging Centre funded by CRUK and EPSRC in association with the MRC and DoH (England), and by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. PET and SPECT scanning equipment was funded by an equipment grant from the Wellcome Trust. IH thanks EU FP7 for Marie Curie CIG 303535. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

**REFERENCES**


